Delcath Systems, Inc. (DCTH)

Market Cap	307.91M
Revenue (ttm)	22.64M
Net Income (ttm)	-34.12M
Shares Out	31.97M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	391,432
Open	9.90
Previous Close	9.91
Day's Range	9.50 - 10.04
52-Week Range	2.60 - 12.88
Beta	0.76
Analysts	Strong Buy
Price Target	21.50 (+123.26%)
Earnings Date	Nov 8, 2024

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Financial Performance

In 2023, Delcath Systems's revenue was $2.07 million, a decrease of -24.05% compared to the previous year's $2.72 million. Losses were -$47.68 million, 30.6% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 123.26% from the latest price.

Price Target

$21.5

(123.26% upside)

Analyst Consensus: Strong Buy